China National Accord Medicines Corporation Ltd
The Third Quarterly Report for 2016
October 2016
Section I. Important Notice
Board of Directors, Supervisory Committee, all directors, supervisors and senior
executives of China National Accord Medicines Corporation Ltd. (hereinafter
referred to as the Company) hereby confirm that there are no any fictitious
statements, misleading statements, or important omissions carried in this report,
and shall take all responsibilities, individual and/or joint, for the reality,
accuracy and completion of the whole contents.
All directors are present the meeting of the Board for deliberating the Third
Quarter Report of the Company in person.
Lin Zhaoxiong, person in charge of the Company, head of the accounting works
Wei Pingxiao and Wang Ying, accounting body principals (accountant in charge)
hereby confirm that the Financial Report of the Third Quarterly Report is
authentic, accurate and complete.
Section II. Main accounting data and changes of shareholders
I. Main accounting data and index
Whether it has retroactive adjustment or re-statement on previous accounting data for accounting policy changed and accounting
error correction or not
□Yes √ No
Current period-end Period-end of last year Increase/decrease
Total assets(RMB) 14,962,096,742.60 13,218,349,735.31 13.19%
Net assets attributable to
shareholders of listed company 6,067,416,420.30 5,453,393,694.55 11.26%
(RMB)
Increase/decrease in
Increase/decrease in
Year-begin to end of comparison with
Current period comparison with same
the Period year-begin to
period of last year
period-end of last year
Operating revenue (RMB) 7,332,379,516.04 6.79% 21,421,432,387.92 8.85%
Net profit attributable to
shareholders of the listed company 180,690,224.79 -3.25% 722,812,308.65 25.91%
(RMB)
Net profit attributable to
shareholders of the listed company
174,075,812.75 -4.89% 578,585,221.16 3.94%
after deducting non-recurring gains
and losses(RMB)
Net cash flow arising from
-- -- 530,039,802.32 29.86%
operating activities(RMB)
Basic earnings per share
0.498 -3.30% 1.993 25.90%
(RMB/Share)
Diluted earnings per share
0.498 -3.30% 1.993 25.90%
(RMB/Share)
Weighted average ROE 3.02% -0.59% 12.56% 1.10%
In RMB
Amount from year-begin to
Item Note
end of the Period
Mainly because the subsidiary
Gains/losses from the disposal of non-current asset (including the
8,589,165.10 Guangxi Logistics disposed the
write-off that accrued for impairment of assets)
assets and obtained income.
Governmental subsidy reckoned into current gains/losses (not
Mainly refers to the various
including the subsidy enjoyed in quota or ration according to
14,445,709.44 specific grants and finance
national standards, which are closely relevant to enterprise’s
discount received in the Period
business)
Reversal of impairment reserve for account receivable with
2,805,960.48
separate impairment testing
Mainly due to the earnings from
render a hosted services by
Income of trustee fee obtained from trust for management 452,044.03 Sinopharm Holding and China
National Pharmaceutical Foreign
Trade Corporation
A default for overdue payments
Other non-operating income and expenditure except for the
2,977,962.60 of equity transfer received from
aforementioned items
third party
Investment gains from disposal of
Subsidiary disposal and gain/losses from long-term investment
121,754,182.26 67% equity of Sinopharm Zhijun
revaluation
Suzhou
Less: impact on income tax 144,750.08
Impact on minority shareholders’ equity (post-tax) 6,653,186.34
Total 144,227,087.49 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss, and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss, explain reasons
□ Applicable √ Not applicable
In reporting period, the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of
extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to
the Public --- Extraordinary Profit/loss.
II. Statement of the total shareholders and shares-held of top ten shareholders at end of the
Period
1. Total number of common shareholders at the end of this report period and top ten common shareholders
In Share
Total preference shareholders
Total common shareholders
with voting rights recovered
13,346
at the end of report period at end of reporting period (if
applicable)
Top ten shareholders
Shareholders Nature of Proportion of Amount of shares Amount of Number of share pledged/frozen
shareholder shares held held restricted shares
State of share Amount
held
Sinopharm Group State-owned
51.00% 184,942,291 74,482,543
Co., Ltd. corporate
HTHK/CMG
FSGUFP-CMG
Overseas
FIRST STATE 2.08% 7,548,119
corporate
CHINA
GROWTH FD
China Securities
Finance State-owned
1.72% 6,229,499
Corporation corporate
Limited
VALUE
Overseas
PARTNERS 1.41% 5,130,353
corporate
CLASSIC FUND
GUOTAI
JUNAN
Overseas
SECURITIES(H 1.40% 5,075,646
corporate
ONGKONG)
LIMITED
New China Life
Insurance
Company Ltd.
Domestic non
－Dividend －
state-owned 1.26% 4,564,263
individual
corporate
bonuses
-018L-FH002
Shen
Domestic non
CITIC Securities state-owned 1.16% 4,198,728
corporate
China SAFE
State-owned
Investments 1.05% 3,804,400
corporate
Limited
TARGET Overseas
0.89% 3,241,799
VALUE FUND corporate
China Merchants
Domestic non
Bank Co., Ltd.
state-owned 0.75% 2,719,445
–Huitianfu
corporate
Medical Service
Flexible Mix
Securities
Investment Funds
Particular about top ten shareholders with un-restrict shares held
Type of shares
Shareholders Amount of un-restrict shares held
Type Amount
RMB ordinary
Sinopharm Group Co., Ltd. 110,459,748 110,459,748
shares
Domestically
HTHK/CMG FSGUFP-CMG FIRST
7,548,119 listed foreign 7,548,119
STATE CHINA GROWTH FD
shares
China Securities Finance RMB ordinary
6,229,499 6,229,499
Corporation Limited shares
Domestically
VALUE PARTNERS CLASSIC
5,130,353 listed foreign 5,130,353
FUND
shares
GUOTAI JUNAN Domestically
SECURITIES(HONGKONG) 5,075,646 listed foreign 5,075,646
LIMITED shares
New China Life Insurance Company
RMB ordinary
Ltd. －Dividend －individual 4,564,263 4,564,263
shares
bonuses -018L-FH002 Shen
RMB ordinary
CITIC Securities 4,198,728 4,198,728
shares
RMB ordinary
China SAFE Investments Limited 3,804,400 3,804,400
shares
Domestically
TARGET VALUE FUND 3,241,799 listed foreign 3,241,799
shares
China Merchants Bank Co., Ltd.
RMB ordinary
–Huitianfu Medical Service Flexible 2,719,445 2,719,445
shares
Mix Securities Investment Funds
Explanation on associated It is unknown that there exists no associated relationship or belongs to the consistent actionist
relationship among the aforesaid among the other tradable shareholders regulated by the Management Measure of Information
shareholders Disclosure on Change of Shareholding for Listed Companies.
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement
dealing in reporting period
□ Yes √ No
The shareholders of the Company have no buy-back agreement dealing in reporting period.
2. Total of shareholders with preferred stock held and the top ten shareholdings
□Applicable √Not applicable
Section III. Important events
I. Particular about major changes from items of main accounting statements and financial
indexes as well as reasons
√ Applicable □Not applicable
1. Monetary fund: increased 524million Yuan over that of peirod-begin with growth rate of 33.38%, mainly because cash in-flow
growth with the soaring sales and money of equity disposal of the subsidiary received;
2. Interest receivable: increased 631,400 Yuan over that of peirod-begin with growth rate of 100.00%, mainly because entrust loans
interest receivable from associated enterprise at period-end;
3. Other account receivable: increased 78.0541 million Yuan over that of peirod-begin with growth rate of 204.46%, mainly because
entrust loans receivable from associated enterprise at period-end;
4. Assets divided into assets ready for sale: decreased 2,456,900 Yuan over that of peirod-begin with growth rate of -100.00%,
mainly because the underlying assets close in the Period;
5. Other current assets: decreased 10.1772 million Yuan over that of peirod-begin with growth rate of -52.31%, mainly because the
overpaid VAT decreased in the Peirod;
6. Long-term equity investment: increased 88.5064 million Yuan over that of peirod-begin with growth rate of 48.94%, mainly
because part of the subsidiary’s equity are disposa in the Period, and resulted by the calculation of equity instead of cost;
7. Development expenditure: decreased 5,619,300 Yuan over that of peirod-begin with growth rate of -100.00%, mainly because
equity of subsidiary dispose in the Period, than corresponding development expenditure declined;
8. Goodwill: decreased 28.0194 million Yuan over that of peirod-begin with growth rate of -35.30%, mainly because equity of
subsidiary dispose in the Period, than corresponding goodwill declined;
9. Deferred income tax assets: decreased 46.5577 million Yuan over that of peirod-begin with growth rate of -52.78%, mainly
because equity of subsidiary dispose in the Period, than corresponding deferred income tax assets declined;
10. Taxes payable: increased 25.0836 million Yuan over that of peirod-begin with growth rate of 34.43%, the accrual income tax
increased due to the growth of profit in the Period;
11. Non-current liability due within one year: increased 31.5446 million Yuan over that of peirod-begin with growth rate of 579.35%,
mainly because the long-term loans are re-divided to non-current liability due within one year;
12. Long-term loans: decreased 72.4952 million Yuan over that of peirod-begin with growth rate of -100.00%, mainly because the
long-term loans are re-divided to non-current liability due within one year;
13. Financial expenses: decreased 27.4838 million Yuan on a y-o-y basis with growth rate of -34.86%, mainly because the loan rate
declined with the decrease of the loans in the Period;
14. Investment income: increased 118 million Yuan on a y-o-y basis with growth rate of 299.27%, mainly because obtained
investment income from disposal of subsidiary’s equity in the Period;
15. Non-operation expenses: increased 1,170,700 Yuan on a y-o-y basis with growth rate of 234.59%, mainly because disposal of
non-current assets has a y-o-y growth in the Period;
16. Refund of tax and levies: increased 13.1249 million Yuan on a y-o-y basis with growth rate of 907.21%, mainly because
receiving more income tax rebates and export rebates over that of last period;
17. Net cash received from disposal of fixed assets, intangible assets and other long-term assets: increased 1,518,400 Yuan on a y-o-y
basis with growth rate of 152.14%, mainly because non-current assets disposal increased from a year earlier;
18. Net cash received from disp
